سعر مورجافلوكس 0.5% محلول معقم للعين 5 مل 2022

Morgaflox 0.5% sterile ophthalmic solution 5 ml (Kahira > Modern Office for Import, Egypt): moxifloxacin, a fluoroquinolone antibacterial eye drop.

• Treatment of bacterial conjunctivitis caused by susceptible strains (e.g. Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae, viridans streptococci, Haemophilus influenzae, Chlamydia trachomatis, Corynebacterium species).Population: All ages (adults, children and neonates)DailyMed (U.S. National Library of Medicine)

• Ocular (about 1-6%): conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, hyperemia, pain, pruritus, subconjunctival hemorrhage, tearing. Non-ocular (1-4%): fever, increased cough, infection, otitis media, pharyngitis, rash, rhinitis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to moxifloxacin, other quinolones or any component of the medication.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious, occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with systemic quinolones; discontinue if an allergic reaction occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Prolonged use may cause overgrowth of non-susceptible organisms including fungi; if superinfection occurs, discontinue and use alternative therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Do not wear contact lenses while there are signs or symptoms of bacterial conjunctivitis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs metabolised by CYP3A4, CYP2D6, CYP2C9, CYP2C19 or CYP1A2No drug-drug interaction studies with the eye drops; in vitro, moxifloxacin does not inhibit these CYP450 isozymes, so it is unlikely to alter their pharmacokinetics.DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; oral (rats, monkeys) and IV (rabbits) moxifloxacin during organogenesis did not cause adverse maternal or fetal effects at clinically relevant doses (effects only at very high multiples of the ophthalmic exposure).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; transferred into rat milk after oral dosing. Systemic levels after ocular use are low; weigh breastfeeding benefits against the mother's need and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Moxifloxacin: Inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes needed for bacterial DNA replication, transcription, repair and chromosome partitioning.